Innovative Surgical Approaches That Improve Individual Outcomes in Advanced Breast Cancer
Int J Womens Health. 2024 Mar 30;16:555-560. doi: 10.2147/IJWH.S447837. eCollection 2024.ABSTRACTBreast cancer is the most common cause of cancer death in women and the second cause in the general population. The incidence has increased over time. Women in developing countries often present at an advanced stage where initial surgery is not feasible. Short disease-free intervals, the number of metastatic organs and liver metastasis were consistently associated with poor overall survival. Surgery is an integral part of the therapeutic plan for locally advanced breast cancer. The integration of surgical care into the manageme...
Source: Cancer Control - April 5, 2024 Category: Cancer & Oncology Authors: Valerii Lu țenco Laura Rebegea Adrian Beznea George Tocu Monica Moraru Oana Mariana Mihailov Bogdan Mihnea Ciuntu Verginia Lu țenco Floris Cristian Stanculea Raul Mihailov Source Type: research
Optimal [(18)F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial
Conclusion: In the PHERGain trial, an increased SUVmax cutoff (≥77%) after 2 cycles of exclusive HP (with or without endocrine therapy) achieves a pCR in the range of the control arm with chemotherapy plus HP (59.5% vs. 57.7%, respectively), further identifying a subgroup of patients with HER2-addicted tumors. However, the original cutoff (≥40%) maximizes the number of patients who could avoid chemotherapy.PMID:38575192 | DOI:10.2967/jnumed.123.266384 (Source: Cancer Control)
Source: Cancer Control - April 4, 2024 Category: Cancer & Oncology Authors: Geraldine Gebhart Marleen Keyaerts Thomas Guiot Patrick Flamen Manuel Ruiz-Borrego Agostina Stradella Bego ña Bermejo Santiago Escriva-de-Romani Lourdes Calvo Mart ínez Nuria Ribelles Mar ía Fernandez-Abad Cinta Albacar Marco Colleoni Laia Garrigos Man Source Type: research
Capivasertib: A Novel AKT Inhibitor Approved for Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast Cancer
CONCLUSION: Integration of capivasertib into clinical practice is ongoing; intermittent dosing and favorable toxicity are attractive for future novel combination prospective trials.PMID:38566315 | DOI:10.1177/10600280241241531 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - April 3, 2024 Category: Drugs & Pharmacology Authors: Alexa J Luboff David L DeRemer Source Type: research
Capivasertib: A Novel AKT Inhibitor Approved for Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast Cancer
CONCLUSION: Integration of capivasertib into clinical practice is ongoing; intermittent dosing and favorable toxicity are attractive for future novel combination prospective trials.PMID:38566315 | DOI:10.1177/10600280241241531 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - April 3, 2024 Category: Drugs & Pharmacology Authors: Alexa J Luboff David L DeRemer Source Type: research
Cancers, Vol. 16, Pages 1405: Clinical and Analytical Validation of Two Methods for Ki-67 Scoring in Formalin Fixed and Paraffin Embedded Tissue Sections of Early Breast Cancer
In this study, Ki-67 was retrospectively evaluated by three pathologists using two methods: a visual assessment of the entire slide and a quantitative assessment of the tumour margin in 411 early-stage breast cancer patients with a median follow-up of 26.8 years. We found excellent agreement between the three pathologists for both methods. The risk of recurrence for Ki-67 was time-dependent, as the high proliferation group (Ki-67 ≥ 30%) had a higher risk of recurrence initially, but after 4.5 years the risk was higher in the low proliferation group. In estrogen receptor (ER)-positive patients, the intermediate K...
Source: Cancers - April 3, 2024 Category: Cancer & Oncology Authors: Sne žana Đokić Barbara Gazi ć Biljana Gr čar Kuzmanov Jerca Blazina Simona Miceska Tanja Čugura Cvetka Gra šič Kuhar Jera Jeruc Tags: Article Source Type: research
The prognosis of patients treated with everolimus for advanced ER-positive, HER2-negative breast cancer is driven by molecular features
J Pathol Clin Res. 2024 May;10(3):e12372. doi: 10.1002/2056-4538.12372.ABSTRACTEverolimus is widely used in patients with advanced ER-positive, HER2-negative breast cancer. We looked at alterations in the PIK3CA/AKT/mTOR pathway in a multicenter cohort as potential biomarkers of efficacy. Patients with advanced ER-positive, HER2-negative breast cancer treated with everolimus and endocrine therapy between 2012 and 2014 in two cancer centers were included. Targeted sequencing examined mutations in PIK3CA, ESR1, and AKT1 genes. An immunochemical analysis was conducted to evaluate expression of PTEN, INPP4B, STK11, p4EBP1, and...
Source: Clinical Breast Cancer - April 2, 2024 Category: Cancer & Oncology Authors: H élène Salaün Lounes Djerroudi Laura Haik Anne Schnitzler Guillaume Bataillon Gabrielle Deniziaut Ivan Bi èche Anne Vincent-Salomon Marc Debled Paul Cottu Source Type: research
The prognosis of patients treated with everolimus for advanced ER-positive, HER2-negative breast cancer is driven by molecular features
J Pathol Clin Res. 2024 May;10(3):e12372. doi: 10.1002/2056-4538.12372.ABSTRACTEverolimus is widely used in patients with advanced ER-positive, HER2-negative breast cancer. We looked at alterations in the PIK3CA/AKT/mTOR pathway in a multicenter cohort as potential biomarkers of efficacy. Patients with advanced ER-positive, HER2-negative breast cancer treated with everolimus and endocrine therapy between 2012 and 2014 in two cancer centers were included. Targeted sequencing examined mutations in PIK3CA, ESR1, and AKT1 genes. An immunochemical analysis was conducted to evaluate expression of PTEN, INPP4B, STK11, p4EBP1, and...
Source: Clinical Genitourinary Cancer - April 2, 2024 Category: Cancer & Oncology Authors: H élène Salaün Lounes Djerroudi Laura Haik Anne Schnitzler Guillaume Bataillon Gabrielle Deniziaut Ivan Bi èche Anne Vincent-Salomon Marc Debled Paul Cottu Source Type: research
Targeting NAD+ metabolism: Pre-clinical insights into potential cancer therapy strategies
Endocrinology. 2024 Apr 3:bqae043. doi: 10.1210/endocr/bqae043. Online ahead of print.ABSTRACTNAD+ is one of the most important metabolites for cellular activities, and its biosynthesis mainly occurs through the salvage pathway using the NAMPT enzyme. The main NAD consumers, PARP and SIRT enzymes, are heavily involved in DNA repair and chromatin remodeling. Since cancer cells shift their energy production pathway, NAD levels are significantly affected. NAD's roles in cell survival led to the use of NAD depletion in cancer therapies. NAMPT inhibition (alone or in combination with other cancer therapies, including endocrine ...
Source: Endocrinology - April 2, 2024 Category: Endocrinology Authors: Ay ça N Mogol Alanna Z Kaminsky David J Dutton Zeynep Madak Erdogan Source Type: research
Targeting NAD+ metabolism: Pre-clinical insights into potential cancer therapy strategies
Endocrinology. 2024 Apr 3:bqae043. doi: 10.1210/endocr/bqae043. Online ahead of print.ABSTRACTNAD+ is one of the most important metabolites for cellular activities, and its biosynthesis mainly occurs through the salvage pathway using the NAMPT enzyme. The main NAD consumers, PARP and SIRT enzymes, are heavily involved in DNA repair and chromatin remodeling. Since cancer cells shift their energy production pathway, NAD levels are significantly affected. NAD's roles in cell survival led to the use of NAD depletion in cancer therapies. NAMPT inhibition (alone or in combination with other cancer therapies, including endocrine ...
Source: Endocrinology - April 2, 2024 Category: Endocrinology Authors: Ay ça N Mogol Alanna Z Kaminsky David J Dutton Zeynep Madak Erdogan Source Type: research
Real-world treatment patterns and clinical outcomes from a retrospective chart review study of patients with recurrent or advanced endometrial cancer who progressed following prior systemic therapy in Europe
Conclusions
Patients had poor clinical outcomes with a median OS of <1 year and rwPFS of approximately 7 months, highlighting the significant unmet medical need in pretreated recurrent/advanced endometrial cancer patients. Novel therapies with potential to improve PFS and OS over conventional therapies could provide significant clinical benefit. (Source: BMJ Open)
Source: BMJ Open - April 2, 2024 Category: General Medicine Authors: Zhang, J., Kelkar, S. S., Prabhu, V. S., Qiao, Y., Grall, V., Miles, N., Marth, C. Tags: Open access, Oncology Source Type: research
Adherence to adjuvant endocrine therapy for breast cancer: a qualitative exploration of attribution of symptoms among post-menopausal women
ConclusionsAET adherence was associated with beliefs about AET, symptom attribution, and symptom management. Routine symptom monitoring during AET and addressing both symptoms and patients ’ understanding of their symptoms may promote adherence to AET. (Source: Supportive Care in Cancer)
Source: Supportive Care in Cancer - April 2, 2024 Category: Cancer & Oncology Source Type: research
Rechallenge of Trastuzumab-based Therapy in HER2-Positive Breast Cancer Patients who Progressed Under TDM-1
This study showed that rechallenge trastuzumab-based therapy was effective and good-tolerated in heavily pretreated patients who had progressed under TDM-1. (Source: Indian Journal of Surgical Oncology)
Source: Indian Journal of Surgical Oncology - April 1, 2024 Category: Cancer & Oncology Source Type: research
Potential Value of HSP90 α in Prognosis of Triple-Negative Breast Cancer
CONCLUSIONS Our research findings demonstrate a significant association between high HSP90alpha expression and adverse clinical features, suggesting a poorer prognosis for TNBC patients.PMID:38553816 | DOI:10.12659/MSM.943049 (Source: Medical Science Monitor)
Source: Medical Science Monitor - March 30, 2024 Category: Research Authors: Han Fei Wang Ying Chen Bang Cao Jing Pei Source Type: research
Pure mucinous adenocarcinoma of the breast with the rare lymphoplasmacytic infiltration: A case report with review of literature
We present the case of a 55-year-old female with a 15-year history of a painless, gradually enlarging palpable lump on her left breast. Upon examination, a 5 × 5 cm lump with well-defined margins and a hard consistency was found in the lower outer quadrant of the left breast. Histopathological examination confirmed a diagnosis of Mucinous Adenocarcinoma of the Left Breast. The patient underwent modified radical mastectomy and received adjuvant endocrine therapy with tamoxifen due to hormone receptor-positive status. Mucinous carcinoma of the breast is a unique entity with specific histological features including the prese...
Source: Clinical Breast Cancer - March 29, 2024 Category: Cancer & Oncology Authors: Yash Hasmukhbhai Prajapati Vishal Bhabhor Kahan Samirkumar Mehta Mithoon Barot Husen Boriwala Mohamed Omar Source Type: research
